Growth in aging population, rise in sedentary lifestyle along with surge in prevalence of cardiovascular diseases (CVDs)

Rise in the geriatric population, increase in the prevalence of cardiovascular diseases, and development in healthcare infrastructure have boosted the growth of the U.S. cardiac resynchronization therapy market. Moreover, high-end technological developments in CRT devices supplemented the market growth. However, product recalls in the U.S., cost of CRT devices, and shortage of healthcare professionals hinder the market growth. On the contrary, developing opportunities in the low economic U.S. states would open lucrative opportunities for the market players.

The U.S. Cardiac Resynchronization Therapy Market was pegged at $965.6 million in 2019, and is projected to reach $983.3 million by 2027, growing at a CAGR of 4.9% from 2020 to 2027.

Cardiac resynchronization therapy (CRT) also known as biventricular pacing or multisite ventricular pacing, is a type of treatment to help correct serious heart rhythm problems. It involves simultaneous pacing of the right ventricle (RV) and the left ventricle (LV). CRT devices assist heart beat efficiently and monitor heart condition, thereby the healthcare professional can provide proper treatment to the patient. Cardiac resynchronization therapy helps in restoring mechanical synchrony by electrically activating the heart in a synchronized manner.

On the basis of application, the intraventricular dyssynchrony segment is anticipated to register the highest CAGR of 5.2% during the forecast period. In addition, the segment dominated the market in terms of revenue in 2019, contributing to more than three-fourths of the market.

Based on end user, the specialized cardiac treatment centers segment is estimated to register the highest CAGR of 6.0% during the forecast period. However, the hospitals segment held the largest share in 2019, accounting for more than three-fifths of the market.

The U.S. cardiac resynchronization therapy market report includes an in-depth analysis of the major market players such as Abbott Laboratories, Osypka Medical GmbH, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, Medtronic plc, LivaNova PLC, MEDICO S.p.A., MicroPort Scientific Corporation, OSCOR Inc., and Lepu Medical Technology (Beijing) Co., Ltd. 

 The presence of favorable reimbursement policies, rise in investments, increase in technological advancements, and a growth in sedentary lifestyle among the U.S. population makes way for the growth of the cardiac resynchronization therapy market in the U.S. In addition, U.S. healthcare spending grew 4.6% in 2019 (as compared to 2018), reaching $3.8 trillion or $11,582 per person is expected to assist in the market growth over the forecast period. 

Kishor Sherkar

Lead Analyst, Healthcare at Allied Market Research